千红制药
(002550)
| 流通市值：52.79亿 | | | 总市值：74.23亿 |
| 流通股本：9.10亿 | | | 总股本：12.80亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 637,459,832.53 | 546,180,633.46 | 684,246,877.47 | 576,225,516.62 |
| 应收票据及应收账款 | 273,302,446.26 | 309,782,029.38 | 286,031,957.37 | 231,931,139.07 |
| 其中：应收票据 | 2,514,328.63 | 3,799,184.82 | 8,203,024.6 | 6,899,289.29 |
| 应收账款 | 270,788,117.63 | 305,982,844.56 | 277,828,932.77 | 225,031,849.78 |
| 应收款项融资 | 22,696,364.06 | 36,043,139.09 | 43,401,801.79 | 43,585,793.21 |
| 预付款项 | 24,635,676.34 | 18,366,292.38 | 8,449,747.17 | 3,900,900.6 |
| 其他应收款合计 | 4,793,365.67 | 6,476,981.72 | 4,631,227.88 | 16,904,047.16 |
| 其中:应收利息 | 1,122,601.23 | 1,122,601.23 | - | - |
| 存货 | 390,770,971.42 | 456,032,492.73 | 499,146,549.6 | 602,010,484.51 |
| 一年内到期的非流动资产 | 110,000,000 | 20,899,800 | - | 64,948,341.46 |
| 其他流动资产 | 4,960,574.91 | 4,394,947.37 | 1,191,655.62 | 14,487,167.55 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,539,683,325.84 | 1,492,494,844.84 | 1,579,634,177.92 | 1,625,976,769.37 |
| 非流动资产: | | | | |
| 债权投资 | 285,397,007.18 | 200,165,027.38 | 209,080,304.12 | 197,241,438.33 |
| 长期股权投资 | 5,150,768.76 | 2,272,108.21 | 5,511,360.8 | 5,978,216.97 |
| 固定资产 | 514,585,372.05 | 528,280,938.17 | 537,921,059.56 | 553,084,121.75 |
| 在建工程 | 9,885,714.17 | 5,957,483.06 | 11,236,245.57 | 8,189,094.55 |
| 无形资产 | 110,256,205.24 | 111,185,113.57 | 112,188,362.85 | 113,138,550.96 |
| 开发支出 | 99,660,827.47 | 86,247,955.23 | 76,471,843.75 | 70,162,324.03 |
| 商誉 | 11,135,053.57 | 11,135,053.57 | 11,135,053.57 | 11,135,053.57 |
| 长期待摊费用 | 22,480,254.94 | 23,397,965.92 | 22,519,407.05 | 23,602,733.69 |
| 递延所得税资产 | 79,365,601.92 | 91,242,121.4 | 93,277,733.06 | 90,526,780.93 |
| 其他非流动资产 | 84,672,030.86 | 77,903,916.6 | 69,745,620 | 67,046,360 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,222,588,836.16 | 1,137,787,683.11 | 1,149,086,990.33 | 1,140,104,674.78 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,762,272,162 | 2,630,282,527.95 | 2,728,721,168.25 | 2,766,081,444.15 |
| 流动负债: | | | | |
| 短期借款 | 20,019,890.41 | 20,021,369.86 | 56,213,623.54 | 55,622,730.9 |
| 应付票据及应付账款 | 50,133,516.92 | 45,485,236.71 | 37,686,119.12 | 41,176,407.88 |
| 应付账款 | 50,133,516.92 | 45,485,236.71 | 37,686,119.12 | 41,176,407.88 |
| 合同负债 | 2,936,545.66 | 3,395,193.23 | 2,144,402.88 | 9,705,888.09 |
| 应付职工薪酬 | 28,944,567.81 | 21,625,848.73 | 19,918,056.2 | 38,855,524.46 |
| 应交税费 | 21,869,117.57 | 22,821,261.71 | 17,618,842.81 | 6,331,619.64 |
| 其他应付款合计 | 12,060,910.6 | 14,693,169.1 | 11,468,729.83 | 7,957,026.27 |
| 其他流动负债 | 49,047,565.33 | 48,993,672.43 | 63,216,588.67 | 46,161,743.29 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 185,012,114.3 | 177,035,751.77 | 208,266,363.05 | 205,810,940.53 |
| 非流动负债: | | | | |
| 递延收益 | 88,321,037.83 | 90,181,538.14 | 82,985,038.45 | 81,845,538.84 |
| 递延所得税负债 | 4,039,061.45 | 4,217,323.4 | 4,307,448.63 | 4,516,468.27 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 92,360,099.28 | 94,398,861.54 | 87,292,487.08 | 86,362,007.11 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 277,372,213.58 | 271,434,613.31 | 295,558,850.13 | 292,172,947.64 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,279,800,000 | 1,279,800,000 | 1,279,800,000 | 1,279,800,000 |
| 资本公积 | 41,653,809.86 | 41,653,809.86 | 41,653,809.86 | 41,653,809.86 |
| 减:库存股 | 170,863,806.25 | 170,863,806.25 | 170,863,806.25 | 30,093,633.31 |
| 其他综合收益 | 495,404.21 | -386,023.7 | -967,007.72 | 355,701.26 |
| 盈余公积 | 289,236,431.28 | 289,236,431.28 | 289,236,431.28 | 289,236,431.28 |
| 未分配利润 | 1,033,587,852.64 | 906,795,040.55 | 978,086,856.27 | 873,978,695.92 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,473,909,691.74 | 2,346,235,451.74 | 2,416,946,283.44 | 2,454,931,005.01 |
| 少数股东权益 | 10,990,256.68 | 12,612,462.9 | 16,216,034.68 | 18,977,491.5 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,484,899,948.42 | 2,358,847,914.64 | 2,433,162,318.12 | 2,473,908,496.51 |
| 负债和股东权益合计 | 2,762,272,162 | 2,630,282,527.95 | 2,728,721,168.25 | 2,766,081,444.15 |
| 公告日期 | 2024-10-18 | 2024-08-16 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |